ASTERDM Aster DM Healthcare Q4 FY26 results (Jan–Mar 2026) and concall
Aster DM Healthcare reported a strong Q4 and full-year FY26, both on a standalone and combined proforma basis with Quality Care. The company saw robust revenue and EBITDA growth, driven by increased patient volumes, improved ARPP IP, and a favorable case mix. The merger with Quality Care is progressing well, with NCLT approval pending. Despite some regional challenges like a nurse strike and competition, management expressed confidence in continued growth and margin expansion through disciplined capacity additions and operational efficiencies.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 18.2%, net profit up 79.1% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 1,086 | 1,050 | 1,000 | 1,078 | 1,197 +10% | 1,186 +13% | 1,182 +18% |
| EBITDA | 217 | 186 | 182 | 202 | 236 +9% | 202 +9% | 224 +23% |
| Net profit | 106 | 64 | 86 | 94 | 121 +14% | 59 −8% | 154 +79% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
